Pembrolizumab companion diagnostic - Merck/NanoString Technologies

Drug Profile

Pembrolizumab companion diagnostic - Merck/NanoString Technologies

Latest Information Update: 03 Jul 2015

Price : $50

At a glance

  • Originator NanoString Technologies
  • Developer Merck & Co; NanoString Technologies
  • Class
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Clinical Phase Unknown Cancer

Most Recent Events

  • 28 May 2015 Clinical trials in Cancer (Diagnosis) in World (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top